Literature DB >> 27634764

Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer.

Cathy Quemener1,2, Jessica Baud1,2, Kevin Boyé1,2, Alexandre Dubrac1,2,3, Clotilde Billottet1,2, Fabienne Soulet1,2, Florence Darlot1,2, Laurent Dumartin1,2, Marie Sire1,2, Renaud Grepin1,2, Thomas Daubon1,2, Fabienne Rayne2,4, Harald Wodrich2,4, Anne Couvelard5, Raphael Pineau1,2, Martin Schilling6, Vincent Castronovo7, Shih-Che Sue8, Kim Clarke9, Abderrahim Lomri1,2, Abdel-Majid Khatib1,2, Martin Hagedorn1,2, Hervé Prats3, Andreas Bikfalvi10,2.   

Abstract

The CXCL4 paralog CXCL4L1 is a less studied chemokine that has been suggested to exert an antiangiogenic function. However, CXCL4L1 is also expressed in patient tumors, tumor cell lines, and murine xenografts, prompting a more detailed analysis of its role in cancer pathogenesis. We used genetic and antibody-based approaches to attenuate CXCL4L1 in models of pancreatic ductal adenocarcinoma (PDAC). Mechanisms of expression were assessed in cell coculture experiments, murine, and avian xenotransplants, including through an evaluation of CpG methylation and mutation of critical CpG residues. CXCL4L1 gene expression was increased greatly in primary and metastatic PDAC. We found that myofibroblasts triggered cues in the tumor microenvironment, which led to induction of CXCL4L1 in tumor cells. CXCL4L1 expression was also controlled by epigenetic modifications at critical CpG islands, which were mapped. CXCL4L1 inhibited angiogenesis but also affected tumor development more directly, depending on the tumor cell type. In vivo administration of an mAb against CXCL4L1 demonstrated a blockade in the growth of tumors positive for CXCR3, a critical receptor for CXCL4 ligands. Our findings define a protumorigenic role in PDAC development for endogenous CXCL4L1, which is independent of its antiangiogenic function. Cancer Res; 76(22); 6507-19. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27634764     DOI: 10.1158/0008-5472.CAN-15-2864

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

2.  Comparative Analysis of the Transcriptome and Proteome during Mouse Placental Development.

Authors:  Majd Abdulghani; Gaoyuan Song; Haninder Kaur; Justin W Walley; Geetu Tuteja
Journal:  J Proteome Res       Date:  2019-04-15       Impact factor: 4.466

3.  CXCL4L1 May Help Differentiate Benign from Malignant Pulmonary Lesions and Predicts Prognosis of Patients with Lung Cancer.

Authors:  Lei Zhang; Guangping Li; Hongxin Zhang; Huaqun Liu; Songlin Li; Yanan Wang; Huisheng Qi
Journal:  Cancer Manag Res       Date:  2022-06-07       Impact factor: 3.602

4.  Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR).

Authors:  K Boyé; C Billottet; N Pujol; I D Alves; A Bikfalvi
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

5.  Tracking cellular and molecular changes in a species-specific manner during experimental tumor progression in vivo.

Authors:  Emilie Indersie; Katarzyna B Hooks; Caroline Capdevielle; Monique Fabre; Nathalie Dugot-Senant; Angélique Desplat; Sébastien Lepreux; Aksam Merched; Christophe F Grosset; Martin Hagedorn
Journal:  Oncotarget       Date:  2018-03-01

6.  The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors.

Authors:  Kevin Boyé; Nadège Pujol; Isabel D Alves; Ya-Ping Chen; Thomas Daubon; Yi-Zong Lee; Stephane Dedieu; Marion Constantin; Lorenzo Bello; Marco Rossi; Rolf Bjerkvig; Shih-Che Sue; Andreas Bikfalvi; Clotilde Billottet
Journal:  Nat Commun       Date:  2017-11-17       Impact factor: 14.919

7.  Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.

Authors:  Mo Zhang; Johnny Guan; Yun-Long Huo; Yong-Sheng Song; Li-Zhu Chen
Journal:  Asian J Androl       Date:  2019 Jul-Aug       Impact factor: 3.285

8.  CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling.

Authors:  Neng Wang; Weiping Liu; Yifeng Zheng; Shengqi Wang; Bowen Yang; Min Li; Juxian Song; Fengxue Zhang; Xiaotong Zhang; Qi Wang; Zhiyu Wang
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

9.  PF4V1, an miRNA-875-3p target, suppresses cell proliferation, migration, and invasion in prostate cancer and serves as a potential prognostic biomarker.

Authors:  Dongyang Li; Xuanyu Hao; Yudi Dong; Mo Zhang; Yongsheng Song
Journal:  Cancer Manag Res       Date:  2019-03-21       Impact factor: 3.989

Review 10.  The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.

Authors:  Nathan Reynders; Dayana Abboud; Alessandra Baragli; Muhammad Zaeem Noman; Bernard Rogister; Simone P Niclou; Nikolaus Heveker; Bassam Janji; Julien Hanson; Martyna Szpakowska; Andy Chevigné
Journal:  Cells       Date:  2019-06-18       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.